Compare Exelixis Inc. Common Stock (EXEL) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Synopsys, Inc. — how do they compare? Exelixis Inc. Common Stock trades at $59.77 (market cap $14.62B), while Synopsys, Inc. trades at $509.81 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 6.5× Exelixis Inc. Common Stock's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 1 Days and Synopsys, Inc. for 71 Days on average.
| EXEL | SNPS | |
|---|---|---|
Market Cap | $14.62B | $95.39B |
Volume | 2,684,957 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $59.13 | $534.56 |
52-Week Low | $34.54 | $367.70 |
Typical Hold Time | 1 Days | 71 Days |
Enterprise Value | $13.95B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $509.99, up 1.46% today, and is near its 52-week high. The stock exhibits a bullish technical trend with strong moving average support. Recent quarterly earnings have consistently beaten estimates, and the company's Investor Day in October 2026 highlighted transformative AI partnerships with OpenAI and Amazon, driving a 13% stock surge and upward revisions to long-term revenue guidance.
The outlook is positive, supported by robust analyst sentiment (93% buy ratings) and a consensus price target of $572.54. Key opportunities include AI-driven growth in chip design software and margin expansion from the Ansys acquisition. Risks involve high valuation multiples and integration execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
